Neurogene Inc. Announces Director Changes and Officer Compensation
Ticker: NGNE · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1404644
Sentiment: neutral
Topics: director-change, officer-compensation, governance
TL;DR
Neurogene's board is shuffling: Leff out, Paul in. Officer pay details also filed.
AI Summary
On June 12, 2025, Neurogene Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Jonathan Leff and the appointment of Dr. Steven M. Paul as a new director. Additionally, the filing covers compensatory arrangements for certain officers and matters submitted to a vote of security holders.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director departures and appointments, along with details on officer compensation, can indicate internal changes that may affect the company's direction and stability.
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Jonathan Leff (person) — Departing Director
- Dr. Steven M. Paul (person) — Appointed Director
- June 12, 2025 (date) — Report Date
FAQ
Who has departed from Neurogene Inc.'s board of directors?
Jonathan Leff has departed from Neurogene Inc.'s board of directors as of June 12, 2025.
Who has been appointed as a new director to Neurogene Inc.'s board?
Dr. Steven M. Paul has been appointed as a new director to Neurogene Inc.'s board.
What other items are covered in this 8-K filing?
The filing also covers compensatory arrangements of certain officers and matters submitted to a vote of security holders.
What is the filing date for this 8-K report?
The 8-K report was filed on June 12, 2025.
What was Neurogene Inc.'s former company name?
Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc. (name change date: 20190812), Aquinox Pharmaceuticals, Inc. (name change date: 20140128), and Aquinox Pharmaceuticals (USA) Inc. (name change date: 20070626).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 by Jonathan Leff regarding Neurogene Inc. (NGNE).